研究人员聚焦于一种新型的固定剂量复方药物，即马西替坦和他达拉非的复方（Macitentan/Tadalafil Fixed-Dose Combination，M/T FDC），这种药物被制成每日服用一次的单药片，旨在为 PAH 患者提供更便捷、有效的治疗方案。该研究成果发表在《Advances in Therapy》上。

Based on the results of SUPER, the FDA-recommended dose for treatment of PAH is 20 mg three-times daily. Tadalafil showed benefit in PAH in the PHIRST trial. [105] This trial enrolled 405 PAH ...

The panel noted that due to existing commissioning arrangement in place for Targeted Therapies for use in Pulmonary Hypertension in Adults, a NICE TA would not add value and the panel subsequently ...

After the FDA approved both combination macitentan/tadalafil (Opsynvi) and the biologic therapy sotatercept (Winrevair) for ...